A groundbreaking study from Mass General Brigham Neuroscience Institute has uncovered crucial genetic underpinnings of congenital cerebral ventriculomegaly (CCV), a disorder characterized by the abnormal swelling of fluid-filled brain ventricles in fetuses. Frequently observed alongside autism spectrum disorder and other neurodevelopmental conditions, CCV has long been a clinical challenge due to its complex origins and unpredictable outcomes.

By analyzing genetic data from approximately 2,700 children diagnosed with CCV and their parents, researchers identified rare, deleterious mutations affecting genes integral to early brain development. These genes regulate the growth and organization of neural cells critical to forming the cerebral cortex—the brain’s center for cognition, memory, and language. Notably, mouse models in which these genes were silenced exhibited enlarged ventricles, linking genetic abnormalities directly to functional and structural brain defects.

This pioneering work shifts the medical understanding of CCV from purely a cerebrospinal fluid circulation disorder to one deeply rooted in developmental brain pathology. It suggests that the ventricular system’s dysfunction reflects a broader impairment in neural circuit formation and brain architecture, potentially explaining why many infants with CCV experience developmental delays and an increased risk of autism.

The implications of these findings are profound. Prenatal neuroimaging combined with targeted genetic screening could enable earlier diagnosis of at-risk fetuses, opening the door to timely interventions before the onset of symptoms. Current neurosurgical treatments, while often lifesaving, do not consistently improve neurological outcomes and expose patients to risks such as infections and lifelong shunt dependency.

Kristopher T. Kahle, MD, PhD, Chief of Pediatric Neurosurgery at Mass General Brigham and senior author of the study, emphasizes the potential of genomic testing to revolutionize patient care. He anticipates that genetic profiling could refine clinical decisions, distinguishing patients who would benefit from surgery from those better served by alternative therapies.

The study’s integration of human genetic analysis with animal modeling represents a paradigm shift, enhancing our grasp of how genetic mutations disrupt cerebrospinal fluid dynamics and cerebral cortex development simultaneously. This dual perspective is poised to stimulate further research aimed at therapeutic innovations targeting the molecular roots of CCV.

Ultimately, this research underscores a critical nexus between developmental neurogenetics and pediatric neurosurgery, offering hope for improved diagnostic precision and personalized treatment strategies. With continued advancements, clinicians may one day prevent or mitigate the neurodevelopmental disabilities often associated with ventriculomegaly, improving quality of life for countless affected children.

Subject of Research: Human tissue samples
Article Title: Developmental genetic determinants of the human cerebrospinal fluid-ventricular system
News Publication Date: —
Web References: https://doi.org/10.1126/scitranslmed.aec4386
References: Allington G et al. Science Translational Medicine. DOI: 10.1126/scitranslmed.aec4386
Keywords: Hydrocephalus, Congenital cerebral ventriculomegaly, Neurodevelopmental disorders, Autism spectrum disorder, Pediatric neurosurgery, Genomic testing

In a groundbreaking fusion of cutting-edge technology and dermatological research, scientists at Biohub have unveiled novel therapeutic targets for psoriasis by conducting the first comprehensive genome-wide CRISPR screen in primary human adult skin cells. By overcoming the longstanding technical hurdle of delivering CRISPR components into notoriously resistant keratinocytes without toxicity, the team utilized centrifuge-based transfection to probe the genetic regulators involved in psoriasis, a chronic inflammatory skin disorder affecting millions globally.

This innovative approach involved knocking out approximately 19,000 genes in keratinocytes sourced from human donors using a vast CRISPR guide RNA library. The focus was on modulating IL17RA, a pivotal receptor that mediates skin inflammation, to chart a genome-wide landscape of genes influencing inflammatory pathways directly in the skin’s outermost layer. The resultant massive data set was then mined using an AI-driven model, VirtualCRISPR, which cross-referenced each gene’s significance against existing scientific literature to highlight previously unrecognized contributors to psoriasis pathology.

Strikingly, this AI-guided screen pinpointed two promising protein targets: ALOX5, an enzyme targeted by the asthma medication zileuton, and OXTR, the gene encoding for the oxytocin receptor, a surprising candidate unassociated before with skin inflammation. Validation experiments in 3D reconstructed human skin cultures demonstrated that zileuton modulates keratinocyte metabolism to suppress inflammation independently from immune cells, revealing a direct pharmacological avenue.

Importantly, topical formulations containing zileuton and cligosiban, an OXTR antagonist, were tested in a mouse model of psoriasis, achieving comparable efficacy to standard injected biologics that broadly suppress immune function. Beyond mitigating inflammation, OXTR inhibition appeared to restore skin barrier integrity—a crucial factor in chronic disease progression—spotlighting this receptor as a novel therapeutic axis.

Unlike current systemic therapies, which often carry risks of broad immunosuppression and high costs, these localized topical interventions promise targeted treatment with minimal systemic exposure. Moreover, the safety profiles of zileuton and OXTR antagonists are well-established in clinical settings, potentially accelerating their repurposing for dermatological applications.

This study exemplifies the transformative power of integrating AI with high-dimensional genetic screening to unravel complex disease mechanisms in cell types previously inaccessible to large-scale functional genomics. By enabling direct investigation into keratinocyte biology, the research not only charts a course for new psoriasis treatments but also sets a precedent for applying similar methodologies to other inflammatory conditions.

As psoriasis affects roughly 125 million people worldwide, innovations enabling precise, effective, and safer therapies could revolutionize patient care. Biohub’s approach heralds a new era where AI-guided CRISPR screens expedite the discovery of unexpected drug targets and foster the development of locally acting, biology-informed treatments.

Subject of Research: Psoriasis therapeutic targets via genome-wide CRISPR screening of human skin cells

Article Title: AI-guided CRISPR screening reveals therapeutic targets in psoriasis

News Publication Date: 8-Jul-2026

Web References:
https://www.nature.com/articles/s41467-026-75249-5

References:
DOI: 10.1038/s41467-026-75249-5

Image Credits: Biohub

Keywords

Psoriasis, CRISPR, Oxytocin receptor, ALOX5, Zileuton, Cligosiban, Keratinocytes, AI-guided screening, Inflammation, Topical therapeutics

A groundbreaking study unveils how the ARP2/3 complex orchestrates the dynamic behavior of neurites, providing fresh insights into neuronal growth and polarity. Researchers utilized advanced optogenetic tools to manipulate RAC1, an upstream regulator of ARP2/3, revealing spatially distinct roles of actin assembly in neuronal morphology.

By employing photoactivatable RAC1 (PA-RAC1), the team demonstrated that ARP2/3-mediated actin assembly at neurite tips promotes growth cone activation and neurite extension. Local activation of PA-RAC1 triggered robust growth cone dynamics, driving neurite elongation. Conversely, activation of a dominant-negative RAC1 mutant led to collapse of the growth cone and neurite retraction, underscoring ARP2/3’s role in sustaining neurite advancement.

Intriguingly, PA-RAC1 activation at the soma induced lamellipodia formation reminiscent of nascent actin waves, which were associated with neurite retraction events. This phenomenon mirrored intrinsic cellular behaviors where somatic actin waves correspond with retracting neurites. The study elegantly showed that the emergence of these waves reduced somatic actin patch intensity, indicating a tightly regulated cytoskeletal oscillator mechanism.

The authors further explored the effects of ARP2/3 inhibition using CK-666 perfusion at distinct cellular locales. When applied over the soma and proximal neurites, CK-666 induced neurite retraction, whereas neurites outside this region continued growing unabated. Notably, actin waves were initiated in neurites outside the inhibited zone, propagating retrogradely toward the soma but dissipating upon entering CK-666-exposed areas. This highlights a spatial dependence of ARP2/3 activity for wave initiation and propagation.

Remarkably, simultaneous activation of PA-RAC1 at multiple growth cones revealed competitive dynamics in actin assembly, with enhanced growth cone activity limited to one or two sites. This suggests an intrinsic cellular mechanism balancing cytoskeletal resources and neurite growth across the complex neuronal arborization.

Together, these findings articulate a dual role for ARP2/3: driving actin wave initiation at the soma that triggers neurite retraction, and supporting growth cone expansion at neurite tips to promote extension. This oscillatory interplay mediated by ARP2/3 and RAC1 underscores the cytoskeleton’s fundamental role in establishing neuronal polarity.

This study not only provides a mechanistic framework for how neurons spatially regulate growth and retraction but also suggests that intrinsic cytoskeletal oscillators underpin the dynamic remodeling necessary for proper neuronal circuit formation. These insights pave the way for future investigations into cytoskeletal dysregulation in neurodevelopmental disorders and neuronal regeneration strategies.

The precise spatial control of actin dynamics mediated by ARP2/3 complex activity advances our understanding of neuronal development, highlighting how local cytoskeletal modulators can dictate overall neuronal architecture through oscillatory growth behaviors.

Subject of Research: Neuronal cytoskeletal dynamics and polarity establishment

Article Title: An intrinsic cytoskeletal oscillator establishes neuronal polarity

Article References:
Lin, Tc., Coles, C.H., Alfadil, E. et al. An intrinsic cytoskeletal oscillator establishes neuronal polarity. Nature (2026). https://doi.org/10.1038/s41586-026-10755-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10755-6